Secukinumab for treating plaque psoriasis

Expert Opinion on Biological Therapy

Volumn 16, Issue 1, 2016, Pages 119-128

  Rothstein, Brooke ^a   Gottlieb, Alice ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

interleukin (IL) 17; plaque psoriasis; psoriatic arthritis; secukinumab; Th17

Indexed keywords

BIOLOGICAL PRODUCT; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MONOCLONAL ANTIBODY; SECUKINUMAB; TUMOR NECROSIS FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; HUMAN; IMMUNOLOGY; METABOLISM; PSORIASIS; QUALITY OF LIFE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKIN-17; PSORIASIS; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955729361     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1121986     Document Type: Review

References (72)

1. Stern RS, Nijsten T, Feldman SR., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9 (2): 136-139
2. Gelfand JM, Weinstein R, Porter SB., et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005; 141 (12): 1537-1541
3. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009; 60 (2): 218-224
4. Menter A, Gottlieb A, Feldman SR., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58: 826-850
5. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007; 370 (9583): 263-271
6. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013; 72 (5): 736-740
7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361 (5): 496-509
8. Gelfand JM, Feldman SR, Stern RS., et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004; 51 (5): 704-708
9. Menter A, Korman NJ, Elmets CA., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011; 65 (1): 137-174
10. Biologic Drugs: Fact Sheets. [cited 2015 Jul 20 ]. Available from: https://www.psoriasis.org/.
11. Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis-best use of biologics. Expert Rev Clin Immunol. 2014; 10 (2): 269-279
12. van Cranenburgh OD, de Korte J, Sprangers MA., et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013; 169 (2): 398-405
13. Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014; 24 (5): 523-532
14. Pathirana D, Ormerod AD, Saiag P., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23 (Suppl 2): 1-70
15. Menter A, Tyring SK, Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58 (1): 106-115
16. Saurat JH, Stingl G, Dubertret L., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158 (3): 558-566
17. Reich K, Nestle FO, Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366 (9494): 1367-1374
18. Menter A, Feldman SR, Weinstein GD., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007; 56 (1): 31.e1-15
19. Leonardi CL, Kimball AB, Papp KA., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371 (9625): 1665-1674
20. Papp KA, Langley RG, Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371 (9625): 1675-1684
21. Leonardi CL, Powers JL, Matheson RT., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349 (21): 2014-2022
22. Griffiths CE, Reich K, Lebwohl M., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386 (9993): 541-551
23. Papp KA, Leonardi C, Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366 (13): 1181-1189
24. Papp K, Leonardi C, Menter A., et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71 (6): 1183-90.e3
25. Lebwohl M, Strober B, Menter A., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015; 373 (14): 1318-1328
26. Amgen to terminate participation in co-development and commercialization of brodalumab. [Press Release] 2015; [cited 2015 Aug 1 ]. Available from: http://www.prnewswire.com/news-releases/amgen-to-terminate-participation-in-co-development-and-commercialization-of-brodalumab-300088098.html
27. AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumab. 2015; [Press Release]. [cited 2015 Oct 29 ]. Available from: https://www.astrazeneca.com
28. Papp KA, Langley RG, Sigurgeirsson B., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013; 168 (2): 412-421
29. Rich P, Sigurgeirsson B, Thaci D., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168 (2): 402-411
30. Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis. [Media Release] 2015; [cited 2015 Aug 23 ]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab
31. Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA., et al. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett. 2015; 20 (1): 1-5
32. Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014; 7: 251-259
33. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. New England J Med. 2009; 361 (9): 888-898
34. Lee E, Trepicchio WL, Oestreicher JL., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004; 199 (1): 125-130
35. Martin DA, Towne JE, Kricorian G., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013; 133 (1): 17-26
36. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012; 167 (4): 717-724
37. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009; 9 (8): 556-567
38. Pappu R, Ramirez-Carrozzi V, Ota N., et al. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010; 30 (2): 185-195
39. Moseley TA, Haudenschild DR, Rose L., et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14 (2): 155-174
40. Pène J, Chevalier S, Preisser L., et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008; 180 (11): 7423-7430
41. Hueber W, Patel DD, Dryja T., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2 (52): 52ra72
42. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129 (6): 1339-1350
43. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol. 2009; 129 (2): 302-308
44. CosentyxTM (secukinumab subcutaneous injection): US prescribing information. Novartis Pharmaceuticals Corporation. 2015; [cited 2015 Sep 10 ]. Available from: http://www.pharma.us.novartis.com
45. Harper EG, Guo C, Rizzo H., et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009; 129 (9): 2175-2183
46. Johansen C, Usher PA, Kjellerup RB., et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160 (2): 319-324
47. Kagami S, Rizzo HL, Lee JJ., et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010; 130 (5): 1373-1383
48. Advisory committee briefing material: Secukinumab (AIN457). 2014; [cited 2015 Sep 10 ]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM419023.pdf
49. European Medicines Agency. Assessment report: Cosentyx (International non-proprietary name: secukinumab). London, UK: European Medicines Agency (EMA) Committee for Medicinal Products for Human use (CHMP); 2014
50. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558
51. Langley RG, Elewski BE, Lebwohl M., et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014; 371 (4): 326-338
52. Paul C, Lacour JP, Tedremets L., et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015; 29 (6): 1082-1090
53. Blauvelt A, Prinz JC, Gottlieb AB., et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172 (2): 484-493
54. Langley RG, Feldman SR, Nyirady J., et al. The 5-point Investigators Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015; 26 (1): 23-31
55. Thaci D, Blauvelt A, Reich K., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015; 73 (3): 400-409
56. McInnes IB, Mease PJ, Kirkham B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999): 1137-1146
57. Mease PJ, McInnes IB, Kirkham B., et al. Secukinumab, a human anti-interluekin-17A monoclonal antibody improves active psoriatic arthritis and inhibits radiograph progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Am Coll Rheumatol. [Abstract 953] 2014; 66: S423-S4
58. Xiong HZ, Gu JY, He ZG., et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8 (3): 3156-3172
59. Eyerich K, Foerster S, Rombold S., et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008; 128 (11): 2640-2645
60. Ye P, Garvey PB, Zhang P., et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001; 25 (3): 335-340
61. Huang W, Na L, Fidel PL., et al. Requirement of interleukin-17A for systemic anti- Candida albicans host defense in mice. J Infect Dis. 2004; 190 (3): 624-631
62. Kagami S, Rizzo HL, Kurtz SE., et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010; 185 (9): 5453-5462
63. Forlow SB, Schurr JR, Kolls JK., et al. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood. 2001; 98 (12): 3309-3314
64. Taylor PR, Roy S, Leal SM Jr., et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR[gamma]t and dectin-2. Nat Immunol. 2014; 15 (2): 143-151
65. Fujino S, Andoh A, Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52 (1): 65-70
66. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011; 140 (6): 1756-1767
67. Hueber W, Sands BE, Lewitzky S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61 (12): 1693-1700
68. Puel A, Doffinger R, Natividad A., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010; 207 (2): 291-297
69. Chandesris MO, Melki I, Natividad A., et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012; 91 (4): e1-19
70. Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients. [Press Release] 2015; [cited 2015 Sep 09 ]. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line.
71. First in the world regulatory approval of Novartis Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis. [Press Release] 2014; [cited 2015 Sep 09 ]. Available from: https://www.novartis.com/news/media-releases/first-world-regulatory-approval-novartis-cosentyxtm-japan-both-psoriasis-and
72. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015; 29 (4): 645-648